3Z-20-001

3Z-20-001 is a repurposed small molecule drug candidate being developed by 3Z Studio for the treatment of various neurological indications. It acts as an agonist at both the alpha-2 adrenergic receptor (α2) and the imidazoline I1 receptor. The drug was identified using 3Z Studio's proprietary zebrafish-based screening platform, which focuses on identifying CNS-active compounds through behavioral analysis. Preclinical proof-of-concept has been established in both zebrafish and rodent models. The development strategy for 3Z-20-001 leverages existing clinical data for a streamlined regulatory path, targeting a New Drug Application (NDA) in the United States and similar pathways in the European Union.